Global Atrial Fibrillation Ablation Device Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Atrial Fibrillation Ablation Device Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Atrial fibrillation is one of the most common arrhythmias, caused by many small reentrant loops guided by the atria. It exists in almost all organic heart diseases, and can also occur in non-organic heart diseases. It can cause serious complications such as heart failure and arterial embolism, and seriously threaten people's health. The goal of Atrial Fibrillation Ablation is to prevent unwanted currents from being transmitted from the pulmonary veins (the blood vessels between the lungs and the heart) to the atrium (the upper chamber of the heart). The standard ablation technique is called pulmonary vein isolation (PVI). During surgery, the catheter is used to ablate (stop) these abnormal electrical signals and prevent them from spreading and continue to cause AFib.

Market Overview:

The latest research study on the global Atrial Fibrillation Ablation Device market finds that the global Atrial Fibrillation Ablation Device market reached a value of USD 1807.3 million in 2022. It’s expected that the market will achieve USD 3318.75 million by 2028, exhibiting a CAGR of 10.66% during the forecast period.

Whether the Covid-19 pandemic persists.

The Covid-19 pandemic has caused severe damage to routine hospital services around the world. Especially countries or regions with severe epidemics are facing the problem of shortage of medical resources. The intensification of the Covid-19 epidemic has brought severe challenges to the normal operation of the global medical system. In related reports, Haytham Kafarani, director of surgery at the Center for Surgical Efficacy and Patient Safety at Massachusetts General Hospital, said that by 2020, the number of operations cancelled due to the epidemic will reach approximately 28.4 million. A large number of operations were cancelled during the epidemic, which means that the demand for medical equipment from medical institutions will be greatly reduced in the short term.

In addition, the global supply chain is affected by the epidemic. Due to the spread of the new coronavirus, many parts and components companies around the world have suspended or postponed their production plans, which will involve medical manufacturing companies. The shortage of upstream companies will also affect atrial fibrillation ablation equipment. Parts manufacturing companies have a negative impact. Reduced orders and supply chain disruption will reduce the use of atrial fibrillation ablation devices.

However, after the epidemic eases, medical institutions will continue to digest cancelled and postponed operations in the next one or two years. Haytham Kafarani said that it will take at least 45 weeks to complete the delayed surgery. Therefore, whether the Covid-19 pandemic will continue in the future will be an important factor in the market for atrial fibrillation ablation devices.

The equipment price is higher.

The high price of equipment is one of the main reasons hindering the adoption rate of less developed countries and a few developing countries. In the next period of time, as the cost of raw materials may continue to rise, the cost and price of equipment will also be adjusted accordingly. Therefore, high price factors will hinder market growth. In addition, the lack of mandatory infrastructure for smooth atrial fibrillation procedures in some emerging regions may hinder the growth of the atrial fibrillation equipment market.

Lack of professionals for surgery.

Atrial fibrillation places high demands on doctors and equipment, and the lack of skilled professionals (such as electrophysiologists, cardiologists, and technicians) is the main factor that may limit market growth. There are many reasons for atrial fibrillation, such as hypertension, hyperthyroidism, coronary heart disease, cardiomyopathy, valvular disease and so on. At the same time, we must also consider whether the patient has complications such as heart failure and stroke. After comprehensive consideration, a reasonable treatment plan can be formulated according to the specific situation of the patient, which will affect the subsequent treatment of the patient. In addition, the standardized treatment of atrial fibrillation needs to increase the medical staff's awareness of atrial fibrillation. Therefore, the standardized treatment of atrial fibrillation requires a higher level of medical equipment and technology.
Therefore, although radiofrequency ablation has a good therapeutic effect, few patients with atrial fibrillation choose to receive this treatment every year. The main reason is that radiofrequency ablation surgery requires high surgical accuracy and equipment flexibility. Therefore, the lack of surgical professionals may hinder the adoption of these devices.

Region Overview:

In 2021, the share of the Atrial Fibrillation Ablation Device market in North America stood at 52.66%.

Company Overview:

Johnson and Johnson is one of the major players operating in the Atrial Fibrillation Ablation Device market, holding a share of 36.88% in 2021.

Johnson and Johnson

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.

The company's major franchises in the Medical Devices segment include Interventional Solutions, Orthopaedics, Surgery (General & Advanced), and Vision.

Abbott

Abbott Laboratories is a U.S. health care company. It specializes in cardiovascular, diagnostics, diabetes and neuromodulation products.

Application Overview:

By application, the Hospitals segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Atrial Fibrillation Ablation Device market covered in Chapter 3:

Cardiofocus
OSYPKA AG
Johnson and Johnson
Synaptic Medical
Boston Scientific
Abbott
Biotroik
Atricure
MicroPort EP MedTech
Japan Lifeline
Medtronic

In Chapter 4 and Chapter 14.2, on the basis of types, the Atrial Fibrillation Ablation Device market from 2018 to 2029 is primarily split into:

Catheter Ablation

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Atrial Fibrillation Ablation Device market from 2018 to 2029 covers:

Hospitals
Ambulatory Surgical Centers
Other

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)